This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
SHSE:688336's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.63 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Sunshine Guojian Pharmaceutical (Shanghai) Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
59.16
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co Median PS Value Related Terms
Sunshine Guojian Pharmaceutical (Shanghai) Co Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co Median PS Value Chart
Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
SHSE:688336 vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Guojian Pharmaceutical (Shanghai) Co Price-to-Median-PS-Value vs Biotechnology Industry
10-Year Median PS Ratio is 0.
Sunshine Guojian Pharmaceutical (Shanghai) Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.753.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a Median PS Value of ¥0.00 as of Jul. 02, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. According to the industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #999999 out of 277 companies in the Biotechnology industry.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's Median PS Value too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current Median PS Value is ¥0.00. Based on the distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #999999 out of 277 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #999999 out of 277 companies for Median PS Value. This places Sunshine Guojian Pharmaceutical (Shanghai) Co in the lower half of its industry. The industry median Median PS Value is 0.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Median PS Value is ¥0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥66.73, compared to a current price of ¥59.16 — trading 11.3% below its estimated fair value. The current Median PS Value is ¥0.00. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current Median PS Value is ¥0.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued.
The current stock price of ¥59.16 is trading 11.3% below its estimated GF Value™ of ¥66.73.
GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Modestly Undervalued.
Key valuation signals for SHSE:688336:
Median PS Value: ¥0.00
GF Value™: ¥66.73 vs. price of ¥59.16 (11.3% below fair value)
No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
85GF Score
Get the complete analysis for SHSE:688336
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688336 has been successfully added to your 
